Cargando…
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867675/ https://www.ncbi.nlm.nih.gov/pubmed/35209919 http://dx.doi.org/10.1186/s12943-022-01534-8 |
_version_ | 1784656101762924544 |
---|---|
author | Kolesar, Jill Peh, Spencer Thomas, Levin Baburaj, Gayathri Mukherjee, Nayonika Kantamneni, Raveena Lewis, Shirley Pai, Ananth Udupa, Karthik S. Kumar AN, Naveena Rangnekar, Vivek M. Rao, Mahadev |
author_facet | Kolesar, Jill Peh, Spencer Thomas, Levin Baburaj, Gayathri Mukherjee, Nayonika Kantamneni, Raveena Lewis, Shirley Pai, Ananth Udupa, Karthik S. Kumar AN, Naveena Rangnekar, Vivek M. Rao, Mahadev |
author_sort | Kolesar, Jill |
collection | PubMed |
description | The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. This review appraises current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic (PGx) testing as precision therapy tools in the management of EGFR mutant and resistant lung cancers. Liquid biopsy could play a potential role in selection of precise tyrosine kinase inhibitor (TKI) therapies during different phases of lung cancer treatment. This selection will be based on the driver EGFR mutational status, as well as monitoring the development of potential EGFR mutations arising during or after TKIs treatment, since some of these new mutations may be druggable targets for alternative TKIs. Several studies have identified the utility of liquid biopsy in the identification of EGFR driver and acquired resistance with good sensitivities for various blood-based biomarkers. With a plethora of sequencing technologies and platforms available currently, further evaluations using randomized controlled trials (RCTs) in multicentric, multiethnic and larger patient cohorts could enable optimization of liquid-based assays for the detection of EGFR mutations, and support testing of CYP450 enzymes and drug transporter polymorphisms to guide precise dosing of EGFR TKIs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01534-8. |
format | Online Article Text |
id | pubmed-8867675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88676752022-02-25 Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers Kolesar, Jill Peh, Spencer Thomas, Levin Baburaj, Gayathri Mukherjee, Nayonika Kantamneni, Raveena Lewis, Shirley Pai, Ananth Udupa, Karthik S. Kumar AN, Naveena Rangnekar, Vivek M. Rao, Mahadev Mol Cancer Review The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. This review appraises current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic (PGx) testing as precision therapy tools in the management of EGFR mutant and resistant lung cancers. Liquid biopsy could play a potential role in selection of precise tyrosine kinase inhibitor (TKI) therapies during different phases of lung cancer treatment. This selection will be based on the driver EGFR mutational status, as well as monitoring the development of potential EGFR mutations arising during or after TKIs treatment, since some of these new mutations may be druggable targets for alternative TKIs. Several studies have identified the utility of liquid biopsy in the identification of EGFR driver and acquired resistance with good sensitivities for various blood-based biomarkers. With a plethora of sequencing technologies and platforms available currently, further evaluations using randomized controlled trials (RCTs) in multicentric, multiethnic and larger patient cohorts could enable optimization of liquid-based assays for the detection of EGFR mutations, and support testing of CYP450 enzymes and drug transporter polymorphisms to guide precise dosing of EGFR TKIs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01534-8. BioMed Central 2022-02-24 /pmc/articles/PMC8867675/ /pubmed/35209919 http://dx.doi.org/10.1186/s12943-022-01534-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Kolesar, Jill Peh, Spencer Thomas, Levin Baburaj, Gayathri Mukherjee, Nayonika Kantamneni, Raveena Lewis, Shirley Pai, Ananth Udupa, Karthik S. Kumar AN, Naveena Rangnekar, Vivek M. Rao, Mahadev Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers |
title | Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers |
title_full | Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers |
title_fullStr | Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers |
title_full_unstemmed | Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers |
title_short | Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers |
title_sort | integration of liquid biopsy and pharmacogenomics for precision therapy of egfr mutant and resistant lung cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867675/ https://www.ncbi.nlm.nih.gov/pubmed/35209919 http://dx.doi.org/10.1186/s12943-022-01534-8 |
work_keys_str_mv | AT kolesarjill integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT pehspencer integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT thomaslevin integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT baburajgayathri integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT mukherjeenayonika integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT kantamneniraveena integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT lewisshirley integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT paiananth integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT udupakarthiks integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT kumarannaveena integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT rangnekarvivekm integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers AT raomahadev integrationofliquidbiopsyandpharmacogenomicsforprecisiontherapyofegfrmutantandresistantlungcancers |